Revvity Slashes Outlook As China Policy Deals Diagnostics Blow - Revvity ( NYSE:RVTY )
Revvity Q2 EPS of $1.18 beat the $1.14 estimate; revenue rose to $720.28 million, topping $710.71 million consensus. FY25 EPS guidance trimmed to $4.85-$4.95 from $4.90-$5.00 due to China DRG policy headwinds. Missed the rally? Learn exactly where the next leaders are emerging here. Revvity Inc.
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - ATAI Life Sciences ( NASDAQ:ATAI ) , Cantor Equity Partners I ( NASDAQ:CEPO )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday. Shares of ATAI Life Sciences NV ATAI fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with ...
Revvity Q2 Revenue Up 4 Percent
Revvity ( NYSE:RVTY ) , a global provider of life sciences and diagnostics tools, released its results for Q2 2025 on July 28, 2025. The company reported GAAP revenue of $720 million, surpassing Wall Street's GAAP estimate of $710.37 million.
Revvity ( RVTY ) Surpasses Q2 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Revvity ( RVTY ) is Poised to Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
Wall Street's Insights Into Key Metrics Ahead of Revvity ( RVTY ) Q2 Earnings
Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
GeneDx Holdings Corp. ( WGS ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity ( RVTY ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Peering Into Revvity's Recent Short Interest - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has fallen 3.26% since its last report. The company recently reported that it has 5.63 million shares sold short, which is 6.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.65 days to cover their ...
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
Pediatrix Medical Group ( MD ) Down 3.1% Since Last Earnings Report: Can It Rebound?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Is the Market Bullish or Bearish on Revvity? - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 8.41% since its last report. The company recently reported that it has 5.11 million shares sold short, which is 6.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.95 days to cover their ...
SynVivo Appoints Dr. Richard Eglen to Board of Directors
HUNTSVILLE, Ala., May 21, 2025 ( GLOBE NEWSWIRE ) -- SynVivo, a pioneering organ-on-chip company developing advanced microfluidic platforms that replicate human tissue microenvironments for drug discovery, today announced the appointment of Dr. Richard Eglen as a non-executive member of its ...
Company News for Apr 29, 2025
Companies In The News Are: DPZ, RVTY, OPRA, INMD.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Revvity ( NYSE:RVTY )
Revvity Q1 sales hit $664.76 million, beating estimates, with adjusted EPS of $1.01, topping consensus of $0.95. 2025 sales outlook raised to $2.85 billion; adjusted EPS guidance affirmed at $4.90-$5.00. Feel unsure about the market's next move?
Revvity ( RVTY ) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Revvity ( RVTY ) Could Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Analysts Estimate Bausch + Lomb ( BLCO ) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Revvity ( RVTY ) Q1 Earnings Expected to Decline
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD Seeks Potential Buyers for Life Sciences Business Division
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
What's Going On With Revvity Stock Today? - Revvity ( NYSE:RVTY )
Revvity's Auto-Pure 2400 platform, approved by the FDA, enhances high-throughput latent TB testing with improved accuracy. RVTY stock rises after FDA approval, boosting lab productivity and supporting faster TB diagnosis and treatment. Feel unsure about the market's next move?
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
Is Revvity Gaining or Losing Market Support? - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 8.68% since its last report. The company recently reported that it has 5.18 million shares sold short, which is 5.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.51 days to cover their ...
Newborn Screening Market Size to Reach US$ 2.69 billion by 2031, Growing at a CAGR of 9.5%, Says The Insight Partners
US & Canada, March 24, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Mar, 24, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners, "Newborn Screening Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report", The newborn ...
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
Molecular Infectious Disease Testing Market to Hit US$17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
Delray Beach, FL,, March 05, 2025 ( GLOBE NEWSWIRE ) -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029.
What Does the Market Think About Revvity? - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 15.51% since its last report. The company recently reported that it has 4.48 million shares sold short, which is 4.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.72 days to cover their ...
Do Options Traders Know Something About Revvity ( RVTY ) Stock We Don't?
Investors need to pay close attention to Revvity (RVTY) stock based on the movements in the options market lately.
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Revvity ( RVTY ) Surpasses Q4 Earnings Estimates
Revvity (RVTY) delivered earnings and revenue surprises of 4.41% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora ( COR ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity Gears Up for Q4 Earnings: What's in the Offing?
RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Revvity ( RVTY ) Earnings Expected to Grow: Should You Buy?
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Revvity ( RVTY ) Beat Estimates Again in Its Next Earnings Report?
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
( RVTY ) - Analyzing Revvity's Short Interest - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 6.45% since its last report. The company recently reported that it has 4.22 million shares sold short, which is 4.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.22 days to cover their ...
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test
Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst - Danaher ( NYSE:DHR ) , Revvity ( NYSE:RVTY )
BofA upgrades Danaher to Buy with a price target of $290 despite challenges in 2024. BofA raises Revvity's rating to Buy, citing growth potential from recent acquisitions and long-term stability. BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Why Is Revvity ( RVTY ) Down 8.7% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Optical Imaging Agent Market Expected to Expand at 8.1% CAGR, Reaching US$ 3,533.2 Million by 2034 | Fact.MR Report
Rockville, MD, Nov. 21, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global optical imaging agent market is estimated to reach a valuation of US$ 1,621.5 million in 2024 and is expected to grow at a CAGR of 8.1% during the forecast ...
NanoCellect Biomedical Announces Strategic Partnership with Additional Distributors Across the APAC Region
San Diego, CA November 08, 2024 -- ( PR.com ) -- NanoCellect Biomedical, a leading provider of innovative microfluidic flow cytometry solutions, is excited to announce new strategic partnerships with additional distributors in the Asia-Pacific ( APAC ) region.
Next Generation Sequencers ( NGS ) Market Set to Surge at 8.3% CAGR, to Reach USD 2.4 billion by 2031 | Transparency Market Research, Inc.
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- The next generation sequencers ( NGS ) industry ( 차세대 시퀀서 ( NGS ) 산업 ) was valued at US$ 1.2 billion in 2022. A CAGR of 8.3% is projected between 2023 and 2031, and the market will reach ...
These Analysts Revise Their Forecasts On Revvity Following Q3 Results - Revvity ( NYSE:RVTY )
Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday. The company posted quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $1.13 per share. The company reported quarterly sales of $684.05 million which beat the analyst consensus ...
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
Revvity ( RVTY ) Surpasses Q3 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of 13.27% and 0.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
